(Q39249689)

10 September 2017

title

Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness (English)

1 reference

10 September 2017

1 reference

neoplastic invasiveness

1 reference

Yoshio Ohno

1

1 reference

10 September 2017

Jun Nakashima

2

1 reference

10 September 2017

Miki Izumi

3

1 reference

10 September 2017

Makoto Ohori

4

1 reference

10 September 2017

Takeshi Hashimoto

5

1 reference

10 September 2017

Masaaki Tachibana

6

1 reference

10 September 2017

publication date

3 November 2012

1 reference

10 September 2017

published in

World Journal of Urology

1 reference

10 September 2017

volume

31

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

359-364

1 reference

10 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Legumain expression as a prognostic factor in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Cell lines used in prostate cancer research: a compendium of old and new lines--part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Antimicrobials and in vitro systems: antibiotics and antimycotics alter the proteome of MCF-7 cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Targeting tumor-associated macrophages as a novel strategy against breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Biomolecular markers of outcome prediction in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0977-Z

Legumain: asparaginyl endopeptidase

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23124822

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23124822

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23124822

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00345-012-0977-Z

1 reference

10 September 2017

1 reference